{"entity":{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","aka":[],"tldr":"A phase 1/2 trial of Elironrasib, Daraxonrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.","summary":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC is a phase 1/2 interventional study registered as NCT06162221 by Revolution Medicines, Inc., with 616 participants planned, started 2024-01-18 and due to reach its primary completion in 2027-06. Interventions recorded: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06162221","url":"https://clinicaltrials.gov/study/NCT06162221"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["elironrasib","daraxonrasib","pembrolizumab","cisplatin","carboplatin","pemetrexed"],"companies":["revolution-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06162221","phase":"1/2","setting":"A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Revolution Medicines, Inc.","enrolled":616,"outcomes":[]},"route":"/trials/nct06162221/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/"},{"id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/"}]}}